Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OPKO HEALTH, INC.

(OPK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPKO HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)

09/03/2021 | 04:49pm EDT

ITEM 1.01. Entry into a Material Definitive Agreement.



On August 30, 2021, BioReference Laboratories, Inc., a New Jersey corporation
("BRLI"), a subsidiary of OPKO Health, Inc., entered into an amended and
restated credit agreement (the "A&R Credit Agreement"), with certain of BRLI's
subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank,
N.A., as administrative agent for the lenders.
The A&R Credit Agreement amended and restated in its entirety that certain
Credit Agreement dated as of November 5, 2015, as amended, by and among BRLI,
certain of its subsidiaries party from time to time thereto, the lenders party
from time to time thereto and JPMorgan Chase Bank, N.A., as administrative agent
for the lenders, and, among other things, (i) made various changes to permit
incurrence of certain secured crossing lien indebtedness, (ii) amended the
interest rate margins applicable to borrowings under the A&R Credit Agreement,
(iii) provided mechanics relating to a transition away from LIBOR as a benchmark
interest rate and replace LIBOR with an alternative benchmark rate and (iv)
extended the maturity date from November 2021 to August, 2024. The A&R Credit
Agreement provides for a revolving credit facility of up to $75 million, which
may be increased by up to an additional $100 million of borrowing availability
subject to certain conditions. As of the date of the A&R Credit Agreement, there
were no borrowings outstanding under the A&R Credit Agreement.
The A&R Credit Agreement contains customary affirmative and negative covenants,
including compliance with a fixed charge coverage ratio and restrictions on the
ability of BRLI and its subsidiaries party to the A&R Credit Agreement to incur
additional indebtedness, incur liens, pay dividends, make certain restricted
payments, consummate certain asset sales, enter into certain transactions with
affiliates, or consolidate or merge with and into another entity.
The foregoing description of the A&R Credit Agreement is only a summary and is
qualified in its entirety by reference to the full text of the A&R Credit
Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and
incorporated by reference herein.
ITEM 9.01.        Financial Statements and Exhibits.


   (d)   Exhibits


 Exhibit No.            Description

10.1                    Amended and Restated Credit Agreement, dated August

30, 2021, by and among by

                        and among BioReference Laboratories, Inc., certain 

of its subsidiaries, and

                        JPMorgan Chase Bank, N.A.
104                     Cover Page Interactive Data File-the cover page 

XBRL tags are embedded within

                        the Inline XBRL document




--------------------------------------------------------------------------------


                                 Exhibit Index
 Exhibit No.            Description

10.1                      Amended and Restated Credit Agreement, dated 

August 30, 2021, by and among

                            by and among BioReference Laboratories, Inc., certain of its
                        subsidiaries, and JPMorgan Chase Bank, N.A.



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about OPKO HEALTH, INC.
10/12KRYSTAL BIOTECH : GeneDx to Offer Free Genetic Testing for Dystrophic Epidermolysis Bullos..
MT
10/12OPKO HEALTH : Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genet..
AQ
09/27PFIZER : And opko announce extension of u.s. fda review of biologics license application o..
AQ
09/24PFIZER : OPKO Health Get FDA Extension for Review of Somatrogon Biologics License Applicat..
MT
09/24Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application ..
GL
09/14OPKO HEALTH : LeaderMed Form Joint Venture to Commercialize Two Drugs in Asia
MT
09/14OPKO HEALTH : LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercial..
AQ
09/14Leadermed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntom..
CI
09/13OPKO HEALTH : Another Diversity Suit Stifled
AQ
09/03OPKO HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
Analyst Recommendations on OPKO HEALTH, INC.
More recommendations